Researchers are taking advantage of small, transparent zebrafish embryos and larvae—and a special strain of see-through adults—to understand the development and spread of cancer.
Researchers are taking advantage of small, transparent zebrafish embryos and larvae—and a special strain of see-through adults—to understand the development and spread of cancer.
Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?
Epigenetic changes accrued over an organism’s lifetime may leave a permanent heritable mark on the genome, through the help of long noncoding RNAs.
On the 10th anniversary of The Scientist’s survey of life science academics, institutions are contending with tighter budgets and larger administrative staffs, while working to sustain and inspire their researchers.
To cope with a growing shortage of hearts, livers, and lungs suitable for transplant, some scientists are genetically engineering pigs, while others are growing organs in the lab.
Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.
After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval.
What can a twentysomething naked mole-rat tell us about fighting pain, cancer, and aging?
What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.
Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.